1. Sommerer C, Zeier M, Meuer S, Giese T. Monitoring of calcineurin inhibitors by NFATregulated gene expression in de novo renal allograft recipients on cyclosporine A. Clin Nephrol 2015;84:165-72.
  2. Keller F, Czock D. NephroPharmacology coming of age. Clin Nephrol 2015;84:127-9.
  3. Czock D, Keller F, Seidling H. Pharmacokinetic predictions for patients with renal impairment: focus on peptides and protein drugs. Br J Clin Pharmacol. 2012;74:66-74.
  4. Sommerer C, Schnitzler P, Meuer S, Zeier M, Giese T. Pharmacodynamic monitoring of cyclosporin a reveals risk of opportunistic infections and malignancies in renal transplant recipients 65 years and older. Ther Drug Monit 2011;33:694-8.
  5. Keller F, Ludwig U, Czock D. Nephropharmacology. Int J Clin Pharmacol Ther. 2006;44:343.
  6. Aymanns C, Voehringer M, Rasche FM, Keller F. Effects of sirolimus on proteinuria and renal function in focal segmental glomerulonephritis. Int J Clin Pharmacol Ther 2006;44:675-6.
  7. Czock D. Pharmacodynamic dose adjustment in renal failure: importance of the Hill coefficient. Int J Clin Pharmacol Ther. 2006;44:474-7.
  8. Meyer B, Guttmann C, Dittrich E, Schmaldienst S, Thalhammer F. Intermittent administration of betalactam-antibiotics for treatment of severe infection in hemodialysis patients. Eur J Med Res 2005;10:140-4.
  9. Czock D, Rasche FM. Dose adjustment of ciprofloxacin in renal failure: reduce the dose or prolong the administration interval? Eur J Med Res 2005;10:145-8.
  10. Hoffmann U, Fischereder M, Reil A, Fischer M, Link J, Krämer BK. Renal effects of gadopentetate dimeglumine in patients with normal and impaired renal function. Eur J Med Res 2005;10:149-54.
  11. Götz AK, Böger CA, Hirschmann C, Schmitz G, Riegger GA, Krämer BK. Effect of HMG-CoA-reductase inhibitors on survival in type 2 diabetes patients with end stage diabetic nephropathy. Eur J Med Res 2005;10:155-60.
  12. Böger CA, Götz AK, Krüger B, Hösl M, Schmitz G, Riegger GA, Krämer BK. Effect of genetic variation on therapy with angiotensin converting enzyme inhibitors or angiotensin receptor blockers in dialysis patients. Eur J Med Res 2005;10:161-8.
  13. Budde K, Fritsche L, Waiser J, Glander P, Slowinski T, Neumayer HH, RADW 102 Renal Transplant Study Group. Pharmacokinetics of the immunosuppressant everolimus in maintenance renal transplant patients. Eur J Med Res 2005;10:169-74.
  14. Schuetz M, Einecke G, Mai I, Neumayer HH, Glander P, Waiser J, Fritsche L, Budde K. Problems of cyclosporine absorption profiling using C2-monitoring. Eur J Med Res 2005;10:175-8.
  15. Scherberich JE, Kellermeyer M, Ried C, Hartinger A. 1-alpha-calcidol modulates major human monocyte antigens and toll-like receptors TLR 2 and TLR4 in vitro. Eur J Med Res 2005;10:179-82.

  16. Former collections of papers

  17. Kidney Blood Press Res. 2004, 27: 159-202.
  18. Int J Clin Pharmacol Ther. 2003, 41: 450–497.
  19. Nephrol Dial Transplant. 1999, 14(Suppl.4): S1–S51.
  20. Int J Clin Pharmacol Ther. 1998, 36: 159–175.
  21. Clin Nephrol. 1995, 43(Suppl.1): S1–S46.
  22. Eur J Clin Pharmacol. 1993, 44(Suppl.1): S1–S68.
  23. Nieren- Hochdruckkr. 1990, 19: 431–518.